Peters Nils, Freilinger Tobias, Opherk Christian, Pfefferkorn Thomas, Dichgans Martin
Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, D-81377 Munich, Germany.
J Neurol Sci. 2007 Sep 15;260(1-2):100-5. doi: 10.1016/j.jns.2007.04.015. Epub 2007 May 24.
HMG-CoA-reductase-inhibitors (statins) exhibit pleiotropic beneficial effects on the vascular system including induction of endothelial nitric oxide synthase (eNOS) expression which is critical for vasodilation. Recent studies suggest a beneficial effect of statins on cerebral vasoreactivity in patients with cerebral small vessel disease (SVD). CADASIL is a monogenic form of SVD caused by mutations in the Notch3 gene. Treatment options are limited and little is known about the therapeutic role of statins in CADASIL.
Twenty-four CADASIL subjects were treated with atorvastatin for 8 weeks. Treatment was started with 40 mg, followed by a dosage increase to 80 mg after 4 weeks. Transcranial Doppler sonography measuring mean flow velocity (MFV) in the middle cerebral artery was performed at baseline and the end of the treatment period. Vasoreactivity was assessed by hypercapnia and intravenous application of l-Arginine, which is the substrate for eNOS.
There was no significant treatment effect on MFV (p=0.5) or cerebral vasoreactivity as assessed by hypercapnia (p=0.5) and intravenous l-Arginine (p=0.4) in the overall cohort. However, an inverse correlation was found between vasoreactivity at baseline and changes of both CO2 and l-Arginine-induced vasomotor response (both p<0.05).
Short term treatment with atorvastatin resulted in no significant improvement of hemodynamic parameters in the overall cohort of CADASIL subjects.
HMG-CoA还原酶抑制剂(他汀类药物)对血管系统具有多效性有益作用,包括诱导对血管舒张至关重要的内皮型一氧化氮合酶(eNOS)表达。最近的研究表明他汀类药物对脑小血管病(SVD)患者的脑血管反应性有有益作用。伴有皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病(CADASIL)是由Notch3基因突变引起的单基因形式的SVD。治疗选择有限,关于他汀类药物在CADASIL中的治疗作用知之甚少。
24名CADASIL受试者接受阿托伐他汀治疗8周。治疗开始时剂量为40mg,4周后剂量增加至80mg。在基线和治疗期末进行经颅多普勒超声检查,测量大脑中动脉的平均流速(MFV)。通过高碳酸血症和静脉注射L-精氨酸(eNOS的底物)评估血管反应性。
在整个队列中,阿托伐他汀治疗对MFV(p=0.5)或通过高碳酸血症(p=0.5)和静脉注射L-精氨酸(p=0.4)评估的脑血管反应性均无显著治疗效果。然而,在基线时的血管反应性与二氧化碳和L-精氨酸诱导的血管舒缩反应变化之间发现呈负相关(两者p<0.05)。
在整个CADASIL受试者队列中,阿托伐他汀短期治疗并未显著改善血流动力学参数。